Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 07:00 ET | Source: Pasithea

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage...
November 24, 2025 07:00 ET | Source: Pasithea

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin...
November 21, 2025 12:35 ET | Source: Pasithea

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
September 16, 2025 07:03 ET | Source: Pasithea

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Tx (Nasdaq: KTTA) activates South Korea trial sites, dosing first NF1 patient in Phase 1/1b NF1 study at Asan Medical Ctr. and Severance Hospital.
September 08, 2025 07:01 ET | Source: Pasithea

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Tx (Nasdaq: KTTA) advances PAS-004 NF1 trial to Cohort 2 (8mg) after SRC confirms safety; interim data from first two cohorts expected Q1 2026.
August 28, 2025 07:02 ET | Source: Pasithea

Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Tx (Nasdaq: KTTA) to present PAS-004 clinical progress at H.C. Wainwright Global Investment Conference on Sept. 10, 2025 in NYC.
January 14, 2025 08:02 ET | Source: Pasithea

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea opens EU trial sites for PAS-004, doses Cohort 4, and plans interim safety data in Q1 2025.